Lupin Ltd.

16 clinical trials · Sponsor

Record	Firm	Date
An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-up Period (NCT07732439)	Lupin Ltd.	2026-08-03
Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders (NCT07154654)	Lupin Ltd.	2025-09-30
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study. (NCT06549400)	Lupin Ltd.	2025-09-12
An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR (NCT07097701)	Lupin Ltd.	2025-09-03
The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 (NCT06523400)	Lupin Ltd.	2025-02-13
Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study. (NCT04622553)	Lupin Ltd.	2021-11-05
Open Label Study in Adolescents and Children With Myotonic Disorders (NCT04624750)	Lupin Ltd.	2021-09-03
Study to Investigate the Efficacy and Safety of Mexiletine in Patients With Myotonic Dystrophy Type 1 and Type 2 (NCT04700046)	Lupin Ltd.	2021-09-03
An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders (NCT04616807)	Lupin Ltd.	2020-12-17
A Study of LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors (NCT05187858)	Lupin Ltd.	2020-09-22
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD (NCT04690556)	Lupin Ltd.	2020-09-14
Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer (NCT03511378)	Lupin Ltd.	2018-03-06

Track Lupin Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.